Targets › ENVELOPE
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: the race on ENVELOPE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ANRS, Emerging Infectious Diseases | 3BNC117-LS broadly neutralizing antibody against HIV-1 envelope protein | ENVELOPE | Phase 2 | HIV/AIDS and Infections | Dec 2026 |
HIV/AIDS and Infections (1)
antibody (1)
ANRS, Emerging Infectious Diseases (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.